Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Partial vs Radical Nephrectomy Evaluated

Urol Oncol; ePub 2017 Dec 15; Venkatramani, et al

Publish date:: January 9, 2018

Partial nephrectomy (PN) resulted in better overall survival than radical nephrectomy (RN) in people with cT1b renal cell carcinoma (RCC), according to a study involving >12,000 individuals. This was not the case in those with cT2 RCC.

Participants with either cT1bN0M0 or cT2N0M0 RCC were identified between 2004 and 2013. They received either partial or radical nephrectomy. Investigators looked at overall survival, 30-day readmission rates, and 30- and 90-day mortality. Among the results:

Patients with cT1b tumors who underwent PN experienced better overall survival.
Unplanned 30-day readmission rate in patients undergoing PN regardless of tumor type was 4.2%, vs 2.9% for RN.
30- and 90-day mortality rates were similar in the PN and RN cohorts.

Citation:

Venkatramani V, Koru-Sengul T, Miao F, et al. A comparison of overall survival and perioperative outcomes between partial and radical nephrectomy for cT1b and cT2 renal cell carcinoma-Analysis of a national cancer registry. [Published online ahead of print December 15, 2017]. Urol Oncol. doi:10.1016/j.urolonc.2017.11.008.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,